GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Cyclically Adjusted PS Ratio

Affymax (Affymax) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Affymax Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Affymax Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Affymax's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Cyclically Adjusted PS Ratio Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Affymax's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Affymax's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Affymax's Cyclically Adjusted PS Ratio falls into.



Affymax Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Affymax's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2014 is calculated as:

For example, Affymax's adjusted Revenue per Share data for the three months ended in Jun. 2014 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=0.001/100.5595*100.5595
=0.001

Current CPI (Jun. 2014) = 100.5595.

Affymax Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200409 0.125 80.121 0.157
200412 0.125 80.290 0.157
200503 0.068 81.555 0.084
200506 0.068 82.062 0.083
200509 0.068 83.876 0.082
200512 0.021 83.032 0.025
200603 0.024 84.298 0.029
200606 0.104 85.606 0.122
200609 3.078 85.606 3.616
200612 0.500 85.142 0.591
200703 0.493 86.640 0.572
200706 0.650 87.906 0.744
200709 0.703 87.964 0.804
200712 1.116 88.616 1.266
200803 1.103 90.090 1.231
200806 1.259 92.320 1.371
200809 1.421 92.307 1.548
200812 1.657 88.697 1.879
200903 1.568 89.744 1.757
200906 1.425 91.003 1.575
200909 1.539 91.120 1.698
200912 1.562 91.111 1.724
201003 1.448 91.821 1.586
201006 2.197 91.962 2.402
201009 0.689 92.162 0.752
201012 0.265 92.474 0.288
201103 0.633 94.283 0.675
201106 0.400 95.235 0.422
201109 0.371 95.727 0.390
201112 0.103 95.213 0.109
201203 1.739 96.783 1.807
201206 0.076 96.819 0.079
201209 0.374 97.633 0.385
201212 0.398 96.871 0.413
201303 0.023 98.209 0.024
201306 0.014 98.518 0.014
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.001 100.560 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affymax  (OTCPK:AFFY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Affymax Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Affymax's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Industry
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010